Axillary Hyperhidrosis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Axillary Hyperhidrosis - Pipeline Review, H1 2016', provides an overview of the Axillary Hyperhidrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Axillary Hyperhidrosis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Axillary Hyperhidrosis - The report reviews pipeline therapeutics for Axillary Hyperhidrosis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Axillary Hyperhidrosis therapeutics and enlists all their major and minor projects - The report assesses Axillary Hyperhidrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Axillary Hyperhidrosis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Axillary Hyperhidrosis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Axillary Hyperhidrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Axillary Hyperhidrosis Overview 6 Therapeutics Development 7 Pipeline Products for Axillary Hyperhidrosis - Overview 7 Axillary Hyperhidrosis - Therapeutics under Development by Companies 8 Axillary Hyperhidrosis - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Axillary Hyperhidrosis - Products under Development by Companies 11 Axillary Hyperhidrosis - Companies Involved in Therapeutics Development 12 Allergan Plc 12 Brickell Biotech, Inc. 13 Dermira Inc. 14 GlaxoSmithKline Plc 15 Revance Therapeutics, Inc. 16 TheraVida, Inc. 17 Axillary Hyperhidrosis - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Combination Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 (oxybutynin chloride + pilocarpine hydrochloride) - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 ANT-1207 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 ANT-1403 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 daxibotulinumtoxin A - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 DRM-04 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 oxybutynin chloride - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 sofpironium bromide - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 umeclidinium bromide - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Axillary Hyperhidrosis - Recent Pipeline Updates 38 Axillary Hyperhidrosis - Product Development Milestones 45 Featured News & Press Releases 45 Mar 07, 2016: BBI-4000 (Sofpironium Bromide) Demonstrates Promising Potential as a Safe and Effective First-line Treatment for Excessive Underarm Sweating 45 Feb 29, 2016: Dermira Completes Patient Enrollment for DRM04 Phase 3 Pivotal Trials in Primary Axillary Hyperhidrosis 46 Jan 07, 2016: Dermira Provides DRM04 Development Program Update 47 Dec 23, 2015: Revance Announces Positive Phase 2 Results for RT001 Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis 48 Dec 17, 2015: Brickell Biotech Achieves Statistically Significant and Clinically Meaningful Phase 2b Results for BBI-4000 in Patients with Hyperhidrosis 49 Sep 28, 2015: Revance Therapeutics Initiates Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Lateral Canthal Lines 49 Sep 09, 2015: Revance Therapeutics Initiates Phase 2 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis 50 Aug 03, 2015: Dermira Doses First Patients in DRM04 Phase 3 Program in Axillary Hyperhidrosis 51 Jun 03, 2015: Revance Therapeutics to Initiate Two Key Trials for RT001, Its Topical Botulinum Toxin Type A Investigational Drug Product Candidate 52 Feb 05, 2015: Dermira Announces Positive Phase 2b Results for DRM04 in Patients with Hyperhidrosis 52 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 54 Disclaimer 55
List of Tables
Number of Products under Development for Axillary Hyperhidrosis, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Products under Development by Companies, H1 2016 11 Axillary Hyperhidrosis - Pipeline by Allergan Plc, H1 2016 12 Axillary Hyperhidrosis - Pipeline by Brickell Biotech, Inc., H1 2016 13 Axillary Hyperhidrosis - Pipeline by Dermira Inc., H1 2016 14 Axillary Hyperhidrosis - Pipeline by GlaxoSmithKline Plc, H1 2016 15 Axillary Hyperhidrosis - Pipeline by Revance Therapeutics, Inc., H1 2016 16 Axillary Hyperhidrosis - Pipeline by TheraVida, Inc., H1 2016 17 Assessment by Monotherapy Products, H1 2016 18 Assessment by Combination Products, H1 2016 19 Number of Products by Stage and Target, H1 2016 21 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 27 Axillary Hyperhidrosis Therapeutics - Recent Pipeline Updates, H1 2016 38
List of Figures
Number of Products under Development for Axillary Hyperhidrosis, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 10 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Targets, H1 2016 20 Number of Products by Stage and Targets, H1 2016 20 Number of Products by Mechanism of Actions, H1 2016 22 Number of Products by Stage and Mechanism of Actions, H1 2016 22 Number of Products by Routes of Administration, H1 2016 24 Number of Products by Stage and Routes of Administration, H1 2016 24 Number of Products by Molecule Types, H1 2016 26 Number of Products by Stage and Molecule Types, H1 2016 26
Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to driRead More...
Global contact lenses market size is estimated to reach USD 12.5 billion by 2020, according to a new industry report by Radiant Insights, Inc. Growing number of ophthalmic disorder observed in global population especially children is likely to driveRead More...
Global automotive electronics market size forecast is likely to reach USD 279.96 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing application scope of these equipments is estimated to drive industry growth. Increasing iRead More...
Global aerosol propellants market is anticipated to reach USD 24.8 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing popularity of personal care and cosmetics products such as hair sprays, deodorants and shaving creamRead More...
Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to moRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.